Nektar Therapeutics $ 22.38 -1.06 (-4.52%)
Volume:
2,067,981
Avg Vol (1m):
1,518,894
Market Cap $:
4.08 Bil
Enterprise Value $:
3.17 Bil
PE Ratio:
0.00
PB Ratio:
3.73
Financial Strength | 7/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 7.07 | ||
| Equity-to-Asset | 0.7 | ||
| Debt-to-Equity | 0.14 | ||
| Debt-to-EBITDA | -0.38 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | 3.22 | ||
| Beneish M-Score | -2.63 | ||
| WACC vs ROIC | |||
Profitability Rank | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -248.45 | ||
| Net Margin % | -290.65 | ||
| ROE % | -35.81 | ||
| ROA % | -26.12 | ||
| ROC (Joel Greenblatt) % | -208.17 | ||
| 3-Year Revenue Growth Rate | -24.3 | ||
| 3-Year EBITDA Growth Rate | -104 | ||
| 3-Year EPS without NRI Growth Rate | -59 |
NKTR
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 3.73 | ||
| PS Ratio | 26.08 | ||
| EV-to-EBIT | -7.78 | ||
| EV-to-EBITDA | -8.06 | ||
| EV-to-Revenue | 20.7 | ||
| Current Ratio | 9.83 | ||
| Quick Ratio | 9.7 | ||
| Days Inventory | 253.94 | ||
| Days Sales Outstanding | 92.83 | ||
| Days Payable | 414.89 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.8 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 4.02 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 9.25 | ||
| Price-to-Median-PS-Value | 2.35 | ||
| Earnings Yield (Greenblatt) % | -12.85 |